Related Experiment Video

Updated: Jun 20, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype

Jui-yu Chen1, Mackenzie R Cook, Scott N Pinchot

  • 1Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, Madison, Wisconsin 53792, USA. chen@surgery.wisc.edu

The Journal of Surgical Research
|September 22, 2009
PubMed
Abstract

Insights

The proteasome inhibitor MG-132 effectively reduces carcinoid cancer growth and neuroendocrine markers. This study suggests MG-132 is a promising therapeutic option for neuroendocrine tumors, warranting further investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Carcinoid cancers are common neuroendocrine tumors with limited treatment options.
  • Glycogen synthase kinase-3beta (GSK-3beta) inhibition is a potential therapeutic target.
  • This study explores MG-132's effect on carcinoid growth and its link to GSK-3beta.

Purpose of the Study:

  • To investigate the efficacy of MG-132, a proteasome inhibitor, in treating carcinoid cancer.
  • To assess MG-132's impact on neuroendocrine phenotype and its association with GSK-3beta.
  • To evaluate MG-132 as a potential therapeutic strategy for carcinoid disease.

Main Methods:

  • Human pulmonary (NCI-H727) and gastrointestinal (BON) carcinoid cells were treated with MG-132.
  • Cellular growth was assessed using the MTT assay.
  • Western blotting was employed to measure GSK-3beta, neuroendocrine markers (CgA, ASCL1), and apoptotic markers (PARP, caspase-3).

Main Results:

  • MG-132 significantly inhibited carcinoid cell growth in a dose-dependent manner.
  • A decrease in neuroendocrine markers (CgA, ASCL1) and an increase in apoptosis markers (cleaved PARP, cleaved caspase-3) were observed.
  • Phosphorylated GSK-3beta levels increased following MG-132 treatment.

Conclusions:

  • MG-132 effectively inhibits carcinoid tumor cell proliferation and diminishes the neuroendocrine phenotype.
  • The observed increase in phosphorylated GSK-3beta suggests a role in MG-132's mechanism of action.
  • MG-132 shows potential as a therapeutic agent for intractable carcinoid disease, meriting further preclinical research.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...